Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
It has >10-fold selectivity over DYRK3 and DYRK2 (IC50 ~800 nM and 900 nM respectively
InChiKey: DZHFTEDSQFPDPP-HWYNEVGZSA-L
Regulated necrosis and its implications in toxicology
The expression of Wnt-target genes (AXIN2
and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration
TraMetinib - CAS# 871700-17-3 0201 It has >10-fold selectivity overTrametinib, also known as GSK1120212, CAS No. 871700 17 3, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in